Tenax Therapeutics

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. $TENX

[Tenax Therapeutics @TenaxThera]

We’re delighted to welcome Dr. Paul van Haelst to the Tenax team! Paul is a seasoned drug development leader in cardiometabolic and cardiogenetic diseases, and we will lean on his expertise as we continue to advance TNX-103 for PH-HFpEF.

#PH #Group2PH

[Tenax Therapeutics @TenaxThera]

We’re delighted to welcome Dr. So-Young Kim to the Tenax team! Dr. Kim’s extensive experience in drug development and commercial strategy will be vital as we continue to advance TNX-103 for PH-HFpEF.

#PH #Group2PH

[Tenax Therapeutics @TenaxThera]

Today, we reported first quarter 2026 financial results and highlighted recent updates. For full details and results, read today’s press release: https://t.co/mAjLwSVUyk

$TENX

[Tenax Therapeutics @TenaxThera]

Attending #HeartFailure26? Connect with Tenax at the upcoming European Society of Cardiology Heart Failure Congress and learn more about TNX-103 for PH-HFpEF and our ongoing Phase 3 trials.

#pulmonaryhypertension #group2PH

[Tenax Therapeutics @TenaxThera]

Today is #WorldPHDay2026. TENX aims to provide meaningful improvement in the QoL of patients living with PH-HFpEF, the most common form of PH and a disease with no approved therapy today.

Learn more: https://t.co/bC14C9cBgO

#pulmonaryhypertension #group2PH #HopeInEveryTrial

[Tenax Therapeutics @TenaxThera]

We’re thrilled to welcome Tim Healey as our new CCO! Tim’s deep industry expertise will be invaluable as we continue advancing our TNX-103 program for patients with PH-HFpEF and preparing for commercial launch.

Read the announcement: https://t.co/lgVws9rICv

#PH #Group2PH #CCO

[Tenax Therapeutics @TenaxThera]

Delighted to welcome Tom Staab as our new CFO! He brings over 25 years of financial and executive experience in healthcare, and joins us at a pivotal time as we continue to advance our TNX-103 program for patients with PH-HFpEF. #pulmonaryhypertension #group2PH #CFO

[Tenax Therapeutics @TenaxThera]

Today, we reported fourth quarter and full year 2025 financial results and highlighted recent updates. For full details and results, read today’s press release: https://t.co/gTKwrg8s63 $TENX

[Tenax Therapeutics @TenaxThera]

Tomorrow! Don’t miss our PH-HFpEF spotlight at #THT2026! Mar 2 | 6:15 PM ET | Omni Seaport Hotel
Register now: https://t.co/z2w3g1aB2f @crfheart
#PHHFpEF #Cardiology #THT2026
#TenaxTherapeutics

[Tenax Therapeutics @TenaxThera]

Countdown to #THT2026! Don’t miss the PH-HFpEF Satellite Symposium on Mar 2 at 6:15 PM ET in Boston. Register now: https://t.co/z2w3g1b8RN
#PHHFpEF #Cardiology @crfheart

[Tenax Therapeutics @TenaxThera]

Join us in Boston for an exciting PH-HFpEF session at #THT2026 @crfheart
Mar 2 | 6:15 PM ET | Omni Seaport Hotel
Register: https://t.co/z2w3g1aB2f
Speakers: Barry Borlaug, @JavedButler1, @HFpEF
Panelists: @BurkhoffMd, @MarcoMetra, Stuart Rich

#PHHFpEF

[Tenax Therapeutics @TenaxThera]

Tune in at 11am ET tomorrow to @PVRI's Living Legends series to watch Tenax CMO Stuart Rich share insights from four decades of pioneering work in #PulmonaryHypertension. Register here: https://t.co/Ubu7ySqEO3
#PH #Group2PH

[Tenax Therapeutics @TenaxThera]

Tenax Therapeutics is advancing TNX‑103 (oral levosimendan) with a Phase 3 program focused on K‑ATP channel activation and volume redistribution.

Join us at #THT2026: Mar 2 | 6:15 PM EST | Boston
Register: https://t.co/z2w3g1aB2f

#PHHFpEF #Group2PH

[Tenax Therapeutics @TenaxThera]

Don’t miss our fireside chat with Tenax CEO Chris Giordano and CBO Doug Randall at the Guggenheim Emerging Outlook Biotech Summit tomorrow at 12:30pm ET. Listen to the webcast here: https://t.co/De3VstFwa2

#Group2PH #pulmonaryhypertension

[Tenax Therapeutics @TenaxThera]

Patients living with PH-HFpEF currently have no approved treatment options, but Tenax is committed to changing that. This #HeartFailureAwarenessWeek, we’re highlighting TNX-103, a potential first-in-class therapy to treat PH-HFpEF. Learn more: https://t.co/bC14C9cBgO

[Tenax Therapeutics @TenaxThera]

Novel therapies are being developed to treat PH-HFpEF.
Join us at #THT2026: March 2 | 6:15 PM EST | Boston
Register: https://t.co/z2w3g1aB2f
#PHHFpEF #Cardiology #InnovationInCare

[Tenax Therapeutics @TenaxThera]

February is #AmericanHeartMonth, and we’re raising awareness for the millions of individuals in the US living with PH-HFpEF. Tenax is developing TNX-103 with the goal of transforming the lives of those affected. Learn more: https://t.co/LDEZpSv6wp

[Tenax Therapeutics @TenaxThera]

PH-HFpEF may be treated through K-ATP channel activation, targeting splanchnic circulation to reduce venous return. You don’t want to miss this discussion!
Register now: https://t.co/z2w3g1aB2f
#PHHFpEF #THT2026 @crfheart

[Tenax Therapeutics @TenaxThera]

Could excessive venous return be an underappreciated driver of PH-HFpEF? A hemodynamic question worth exploring.
Join us for this important conversation!
📅 #THT2026 | Mar 2 | 6:15 PM EST | Boston
Register: https://t.co/z2w3g1aB2f

#PHHFpEF #Cardiology #HeartFailureAwareness

[Tenax Therapeutics @TenaxThera]

Pulmonary hypertension complicates ~50% of HFpEF cases, associated with poor outcomes, yet no approved therapies exist. It’s time for a change.

📅 #THT2026 | March 2 | 6:15 PM EST | Boston, MA

Register: https://t.co/z2w3g1aB2f

#Cardiology #PHHFpEF #THT2026 #TenaxTherapeutics